MADRID — Johnson & Johnson’s combination treatment for a common mutation of non-small cell lung cancer kept cancer at bay for longer than AstraZeneca’s Tagrisso — the longtime standard of care for these patients — according to results from a large clinical trial presented at the European Society for Medical Oncology’s annual meeting.
The positive MARIPOSA study results, presented Monday, led J&J to claim that the combination “represents a new standard of care in patients with first-line, EGFR-mutant advanced NSCLC” — though several oncologists questioned the validity of the statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.